Avenue Therapeutics Inc (ATXI)
$2.83
+0.03
(+1.07%)▲
Performance
- $2.77$2.87$2.83
2.12%
Downside
Day's Volatility :3.56%
Upside
1.48%
- $2.25$64.27$2.83
20.49%
Downside
52 Weeks Volatility :96.5%
Upside
95.6%
Returns
| Period | Avenue Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -16.27% | 0.0% |
6 Months | -78.36% | 0.0% |
1 Year | -94.86% | 0.0% |
3 Years | -99.85% | -22.3% |
Highlights
Market Capitalization | 4.0M |
Book Value | $4.0 |
Earnings Per Share (EPS) | 37.48 |
PE Ratio | 0.08 |
PEG Ratio | 0.0 |
Wall Street Target Price | 12.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -201.35% |
Return On Equity TTM | -535.1% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | 37.48 |
Quarterly Earnings Growth YOY | -0.76 |
EPS Estimate Current Year | -6.36 |
EPS Estimate Next Year | -3.14 |
EPS Estimate Current Quarter | -1.05 |
EPS Estimate Next Quarter | -1.11 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 324.03%
Technicals Summary
Sell
Neutral
Buy
Avenue Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Avenue Therapeutics Inc | 20.94% | -78.36% | -94.86% | -99.85% | -99.96% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Avenue Therapeutics Inc | 0.08 | 0.08 | 0.0 | -6.36 | -5.35 | -2.01 | NA | 4.0 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Avenue Therapeutics Inc | Buy | $4.0M | -99.96% | 0.08 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Avenue Therapeutics Inc
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 132.0%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 169.0%
Institutional Holdings
Armistice Capital, LLC
5.24%Sabby Management LLC
2.61%
Company Information
avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.
Organization | Avenue Therapeutics Inc |
Employees | 3 |
CEO | Dr. Alexandra MacLean M.D. |
Industry | Health Technology |
Discover More
A Spac I Acquisition Corp
$2.83
+1.07%
Keyarch Acquisition Corp
$2.83
+1.07%
Connexa Sports Technologies Inc
$2.83
+1.07%
Us Value Etf
$2.83
+1.07%
First Wave Biopharma Inc
$2.83
+1.07%
Global X Msci Next Emerging
$2.83
+1.07%
Fat Projects Acquisition Corp
$2.83
+1.07%
Capital Link Global Fintech
$2.83
+1.07%
Applied Uv Inc
$2.83
+1.07%